Upper Respiratory Tract Infections Clinical Trial
Official title:
A Clinical Study to Determine if Beta-glucan Reduces the Incidence, Duration or Severity of Upper Respiratory Tract Infections Among Skiers
This study is designed to determine if a dieatary supplement containing beta-glucan can reduce the incidence, severity and duration of upper respiratory tract infections among a group of highly trained athletes
In this study, we hypothesize that consumption of 200 mg beta-glucan per day will lessen the frequency, duration and severity of URTI symptoms in a population of elite, internationally competitive skiers over a 45-day period. In order to complete this objective, we will utilize the Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) to monitor and quantify the incidence, duration and severity of URTI symptoms. A secondary objective is to determine if beta-glucan supplementation reduces or mitigates early indictors of athlete-specific stress. This objective will be assessed using the Athlete Psychological Strain Questionnaire (APSQ), a 10-question patient-reported outcome tool used to evaluate athlete-specific psychological stress. This will be a randomized, double blind, placebo controlled, parallel arm design conducted over a 6-week period. 50-60 healthy subjects will be recruited and randomized in a 1:1 ratio to either of two interventions: 1. Placebo: daily consumption of the placebo tablet 2. Treatment: daily consumption of the supplement (treatment) tablet In addition, subjects will complete the WURSS-24 survey daily, and the APSQ survey weekly. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01158560 -
A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT00965822 -
A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population
|
Phase 2 | |
Completed |
NCT01019889 -
Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection
|
Phase 3 | |
Not yet recruiting |
NCT05484102 -
Preventive Effect of Cow's Milk Fermented With Lactobacillus Paracasei CBA L74 on Common Infectious Diseases in Children
|
N/A | |
Recruiting |
NCT05804123 -
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
|
N/A | |
Terminated |
NCT01964885 -
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT01773824 -
Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care
|
N/A | |
Completed |
NCT01883427 -
Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
|
Phase 2 | |
Completed |
NCT01215682 -
Vitamin D Supplementation and Upper Respiratory Tract Infections in Adolescent Swimmers
|
N/A | |
Completed |
NCT04019730 -
The Effect of a Ketogenic Diet on the Exercise Induced Immune Response
|
N/A | |
Completed |
NCT01604096 -
Controlled Trial to Evaluate a Local Information Campaign on Antibiotic Prescribing in Italy
|
Phase 2 | |
Recruiting |
NCT06149494 -
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
|
Phase 2 | |
Completed |
NCT03463694 -
Edinburgh and Lothian Virus Intervention Study in Kids
|
N/A | |
Completed |
NCT06127186 -
Phenotype of Headache and Facial Pain in Upper Respiratory Tract Infections
|
||
Completed |
NCT03198676 -
A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production
|
Phase 1 | |
Withdrawn |
NCT05557214 -
Reducing Unnecessary Antibiotic Prescriptions in Primary Healthcare in Saskatchewan by Identifying High Prescribers
|
N/A | |
Completed |
NCT01893762 -
Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes
|
N/A | |
Completed |
NCT01129128 -
Three Arm Trial of Immune Effects of Echinacea
|
N/A | |
Completed |
NCT01396889 -
Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years
|
N/A | |
Completed |
NCT05252468 -
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
|
N/A |